Sildenafil sublingual - Kedem Pharmaceuticals

Drug Profile

Sildenafil sublingual - Kedem Pharmaceuticals

Alternative Names: GLV-0901; X-Excite

Latest Information Update: 11 Nov 2011

Price : $50

At a glance

  • Originator Global Health Ventures
  • Developer Kedem Pharmaceuticals
  • Class Erectile dysfunction therapies; Phenyl ethers; Piperazines; Purines; Small molecules; Sulfones
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Clinical Phase Unknown Erectile dysfunction

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 07 Nov 2011 Global Health Ventures is now called Kedem Pharmaceuticals
  • 22 Jun 2011 Pharmacokinetics data from a phase I trial in Erectile dysfunction released by Global Health Ventures
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top